KRYS
$316.58-4.07%
as of close, Oct 16, 2026
☾ AH $316.58 -4.07%
Krystal Biotech Inc.Stock · HealthcareRussell 2000 0.3%Nasdaq Composite 0.02%US Stock Market 0.01%Russell 3000 0.01%
KRYS — Krystal Biotech Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeEEEE
50.0100.0150.0200.0250.0300.0350.0010.0M$316.58—20172020202220242026
2026-10-16
Price$316.58
MA20$341.18
MA50$291.07
Vol226.2K
Key stats#
Price data
- Price
- $316.58
- YTD price return
- +28.41%
- YTD total return
- +28.41%
- Next earnings
- Nov 2, 2026
- Market cap
- 9.4B
- Enterprise value
- 8.5B
- Shares outstanding
- 29.6M
- 52W low
- $183.03
- 52W high
- $382.54
- From 52W high
- -17.24%
- From 52W low
- +72.97%
- 52W range
- 67%
Volume
- Rel volume
- 0.79×
- 30D volume
- 285.1K
- 30D $ vol
- 95.7M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- −$26.2M
- Insider net 1Y
- −$83.3M
Form 4 transactions by trade date, as filed; latest on file 2026-09-04.
Fundamentals
- Sales (ttm)
- 440.5M
- Sales/share
- $14.88
- EPS (ttm)
- $7.96
- FCF (ttm)
- 257.8M
- FCF/share
- $8.71
- Book value/share
- $45.92
- Net margin
- 54.82%
- ROE
- 17.77%
- ROA
- 16.09%
- Current ratio
- 8.32
Growth (CAGR, ttm) · 10Y
- Sales
- +22.64%n/an/an/a
- Net income
- +64.63%n/an/an/a
- FCF
- +39.04%n/an/an/a
- Shares
- +2.27%+4.32%+5.92%n/a
Per-share growth (CAGR, ttm) · 10Y
- EPS
- +62.13%n/an/an/a
- Sales/share
- +19.93%n/an/an/a
- FCF/share
- +35.96%n/an/an/a
- Book value/share
- +27.73%+31.25%+19.50%+94.54%
- Price
- +68.16%+40.55%+45.37%n/a
- Total return
- +68.16%+40.55%+45.37%n/a
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 39.8×
- Fwd P/E
- 34.6×
- P/S (ttm)
- 21.3×
- P/B (mrq)
- 6.9×
- P/FCF (ttm)
- 36.4×
- EV/EBITDA (fy)
- 41.9×
- EV/Sales (ttm)
- 19.4×
- FCF yield (ttm)
- 2.75%
- Buyback yield (realized, 1y)
- -2.27%
- Shareholder yield (realized, 1y)
- -2.27%
- Buyback yield (cash, ttm)
- 0.00%
- Shareholder yield (cash, ttm)
- 0.00%
Vs own 10Y history
- P/B
- 94th
Bar = where today’s multiple sits in KRYS’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-16#
1D
-4.07%
5D
-4.53%
1M
-5.97%
3M
-7.38%
YTD
+28.41%
1Y
+68.10%
5Y
+549.79%
Recent filings#
- Aug 14Insider sale · ROSSI DINO A (Director) sold 25,000 shares for $8.2M at $325.60–$333.23
- Aug 3Earnings · Earnings release — EPS $1.79 vs $1.70 est. (+5.3%); revenue $119.2M (+24% y/y) 8.4%
Financial statements
Open full KRYS financials →Loading financial statements…
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +10.48% | +0.43% |
| JNJ | Johnson & Johnson | -4.38% | +0.90% |
| ABBV | AbbVie Inc. | +8.73% | +0.71% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +6.97% | -1.29% |
| MRK | Merck & Co. Inc. | +0.72% | +0.52% |
| NVS | Novartis AG | +8.59% | +0.16% |
| TMO | Thermo Fisher Scientific Inc. | +6.41% | -0.93% |
| AMGN | Amgen Inc. | +14.92% | -0.35% |
